Edwards Lifesciences Corp Q2 2023 Earnings Call Transcript - Thomson StreetEvents

Edwards Lifesciences Corp Q2 2023 Earnings Call Transcript

Edwards Lifesciences Corp Q2 2023 Earnings Call Transcript - Thomson StreetEvents
Edwards Lifesciences Corp Q2 2023 Earnings Call Transcript
Published Jul 26, 2023
Published Jul 26, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of EW.N earnings conference call or presentation 26-Jul-23 9:00pm GMT

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Edwards Lifesciences Corp
Ticker
EW.N
Time
9:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Great. Congrats on a nice quarter. Maybe to start, global TAVR growth around 10%, a little weak in Japan. Where do you think we are in the recovery process in terms of stabilizing the systems, stabilizing time lines and staffing in the system? And when do you think we'll get to a new normal in TAVR procedures and diagnosis and treatment?

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Great. And maybe just kind of a similar question. TMTT, you beat in the quarter, that seems like it was even a bit more impaired over the past few years than the whole TAVR complex. Maybe just talk about mitral and tricuspid, particularly the launch of PASCAL in the U.S., how you think adoption is going versus plan? How you're seeing the competitive situation play out? And just your thoughts on TMTT in general relative to TAVR normalization?

Question: Danielle Joy Antalffy - UBS Investment Bank, Research Division - Analyst : Bernard or maybe, Larry, just on TAVR, 2 questions there. Number one, one of the things everyone's sort of trying to figure out as we move through Q2, is it impacted backlog. I know the high acuity nature of the TAVR procedure are likely not much backlog, and I know you did benefit marginally in Q1. Just curious if you think you saw any of that work down in Q2? That's the first question. Second question is just over the last few quarters, you gave some color on high volume versus low-volume centers driving a lot of the growth. Just

Table Of Contents

Edwards Lifesciences Corp Q3 2023 Earnings Call Summary – 2023-10-25 – US$ 54.00 – Edited Brief of EW.N earnings conference call or presentation 25-Oct-23 9:00pm GMT

Edwards Lifesciences Corp Investor and Analyst TAVR Q&A Session at TCT Transcript – 2023-10-25 – US$ 54.00 – Edited Transcript of EW.N conference call or presentation 25-Oct-23 1:00am GMT

Edwards Lifesciences Corp Q3 2023 Earnings Call Transcript – 2023-10-25 – US$ 54.00 – Edited Transcript of EW.N earnings conference call or presentation 25-Oct-23 9:00pm GMT

Edwards Lifesciences Corp at Wells Fargo Healthcare Conference Transcript – 2023-09-07 – US$ 54.00 – Edited Transcript of EW.N presentation 7-Sep-23 3:00pm GMT

Edwards Lifesciences Corp Q2 2023 Earnings Call Summary – 2023-07-26 – US$ 54.00 – Edited Brief of EW.N earnings conference call or presentation 26-Jul-23 9:00pm GMT

Edwards Lifesciences Corp Q1 2023 Earnings Call Summary – 2023-04-26 – US$ 54.00 – Edited Brief of EW.N earnings conference call or presentation 26-Apr-23 9:00pm GMT

Edwards Lifesciences Corp Q1 2023 Earnings Call Transcript – 2023-04-26 – US$ 54.00 – Edited Transcript of EW.N earnings conference call or presentation 26-Apr-23 9:00pm GMT

Edwards Lifesciences Corp at Cowen Health Care Conference Transcript – 2023-03-07 – US$ 54.00 – Edited Transcript of EW.N presentation 7-Mar-23 3:30pm GMT

Edwards Lifesciences Corp Q4 2022 Earnings Call Summary – 2023-01-31 – US$ 54.00 – Edited Brief of EW.N earnings conference call or presentation 31-Jan-23 10:00pm GMT

Edwards Lifesciences Corp Q4 2022 Earnings Call Transcript – 2023-01-31 – US$ 54.00 – Edited Transcript of EW.N earnings conference call or presentation 31-Jan-23 10:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Edwards Lifesciences Corp Q2 2023 Earnings Call Transcript" Jul 26, 2023. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-Edwards-Lifesciences-Corp-Earnings-Call-T15665218>
  
APA:
Thomson StreetEvents. (2023). Edwards Lifesciences Corp Q2 2023 Earnings Call Transcript Jul 26, 2023. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-Edwards-Lifesciences-Corp-Earnings-Call-T15665218>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.